Sectoral Asset Management Inc is an investment fund managing more than $246 billion ran by Marina Lalakin. There are currently 97 companies in Mrs. Lalakin’s portfolio. The largest investments include Lilly Eli & Co and Lenz Therapeutics, together worth $39.9 billion.
As of 6th August 2024, Sectoral Asset Management Inc’s top holding is 23,415 shares of Lilly Eli & Co currently worth over $21.2 billion and making up 8.6% of the portfolio value.
In addition, the fund holds 1,084,404 shares of Lenz Therapeutics worth $18.7 billion.
The third-largest holding is Contineum Thera worth $14.1 billion and the next is Unitedhealth Grp Inc worth $13.6 billion, with 26,675 shares owned.
Currently, Sectoral Asset Management Inc's portfolio is worth at least $246 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Sectoral Asset Management Inc office and employees reside in Montreal, Quebec, Canada. According to the last 13-F report filed with the SEC, Marina Lalakin serves as the Chief Compliance Officer at Sectoral Asset Management Inc.
In the most recent 13F filing, Sectoral Asset Management Inc revealed that it had opened a new position in
Contineum Thera and bought 800,887 shares worth $14.1 billion.
The investment fund also strengthened its position in Lenz Therapeutics by buying
15,729 additional shares.
This makes their stake in Lenz Therapeutics total 1,084,404 shares worth $18.7 billion.
On the other hand, there are companies that Sectoral Asset Management Inc is getting rid of from its portfolio.
Sectoral Asset Management Inc closed its position in Centene on 13th August 2024.
It sold the previously owned 34,000 shares for $2.67 billion.
Marina Lalakin also disclosed a decreased stake in Lilly Eli & Co by approximately 0.1%.
This leaves the value of the investment at $21.2 billion and 23,415 shares.
The two most similar investment funds to Sectoral Asset Management Inc are Next Capital Management and Hgc Investment Management. They manage $246 billion and $246 billion respectively.
Sectoral Asset Management Inc’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 44.8% of
the total portfolio value.
The fund focuses on investments in the United States as
43.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
29% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $63.6 billion.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Lilly Eli & Co |
8.77%
23,415
|
$21,199,473,000 | 8.62% |
| Lenz Therapeutics |
1.47%
1,084,404
|
$18,749,345,000 | 7.62% |
| Contineum Thera |
Opened
800,887
|
$14,103,620,000 | 5.73% |
| Unitedhealth Grp Inc |
15.10%
26,675
|
$13,584,511,000 | 5.52% |
| Merck & Co Inc |
No change
86,500
|
$10,708,700,000 | 4.35% |
| Johnson & Johnson |
18.81%
56,850
|
$8,309,196,000 | 3.38% |
| Abbvie Inc |
27.70%
44,950
|
$7,709,824,000 | 3.13% |
| Abbott Labs |
5.69%
66,248
|
$6,883,830,000 | 2.80% |
| Regeneron Pharmctcls |
14.63%
6,040
|
$6,348,221,000 | 2.58% |
| Thermo Fisher Sci |
4.99%
10,515
|
$5,814,795,000 | 2.36% |
| Boston Scientific Corp. |
17.35%
71,476
|
$5,504,367,000 | 2.24% |
| Mineralys Therapeuti |
20.55%
438,748
|
$5,133,352,000 | 2.09% |
| Pfizer Inc. |
4.22%
181,400
|
$5,075,572,000 | 2.06% |
| Gilead Sciences, Inc. |
77.82%
68,825
|
$4,722,083,000 | 1.92% |
| Medtronic Plc |
56.50%
59,551
|
$4,687,259,000 | 1.90% |
| AMGEN Inc. |
8.61%
14,700
|
$4,593,015,000 | 1.87% |
| Danaher Corp. |
No change
17,725
|
$4,428,591,000 | 1.80% |
| Stryker Corp. |
94.70%
12,850
|
$4,372,213,000 | 1.78% |
| Vertex Pharma |
19.97%
8,650
|
$4,054,428,000 | 1.65% |
| Dexcom Inc |
0.77%
32,150
|
$3,645,167,000 | 1.48% |
| Biomarin Pharmac Inc |
20.10%
41,260
|
$3,396,936,000 | 1.38% |
| IQVIA Holdings Inc |
10.64%
15,600
|
$3,298,464,000 | 1.34% |
| Alnylam Pharmacuetcl |
32.39%
12,480
|
$3,032,640,000 | 1.23% |
| Zimmer Biomet Hlds |
10.42%
26,650
|
$2,892,325,000 | 1.18% |
| Argenx Se |
29.92%
6,522
|
$2,804,721,000 | 1.14% |
| Centene Corp. |
Closed
34,000
|
$2,668,320,000 | |
| Boundless Bio Inc |
20.28%
682,274
|
$2,640,400,000 | 1.07% |
| Moderna Inc |
50.00%
22,110
|
$2,625,563,000 | 1.07% |
| Vaxcyte, Inc. |
296.82%
33,730
|
$2,546,952,000 | 1.04% |
| Icon Plc |
1.07%
8,028
|
$2,516,537,000 | 1.02% |
| Elevance Health Inc |
28.57%
4,500
|
$2,438,370,000 | 0.99% |
| Intuitive Surgic Inc |
11.48%
5,400
|
$2,402,190,000 | 0.98% |
| CVS Health Corp |
Opened
39,000
|
$2,303,340,000 | 0.94% |
| BioNTech SE |
673.48%
27,265
|
$2,191,015,000 | 0.89% |
| Amicus Therapeutics Inc |
1.90%
216,844
|
$2,151,092,000 | 0.87% |
| Sarepta Therapeutics Inc |
21.95%
13,496
|
$2,132,368,000 | 0.87% |
| GoodRx Holdings, Inc. |
17.45%
265,000
|
$2,067,000,000 | 0.84% |
| Ars Pharmaceuticals |
15.90%
236,937
|
$2,016,334,000 | 0.82% |
| Progyny Inc |
7.89%
70,000
|
$2,002,700,000 | 0.81% |
| Cytokinetics Inc |
13.39%
36,883
|
$1,998,321,000 | 0.81% |
| Inari Med Inc |
22.86%
40,500
|
$1,950,075,000 | 0.79% |
| Eyepoint Pharma |
Closed
92,340
|
$1,908,668,000 | |
| Alphatec Holdings In |
Closed
136,000
|
$1,875,440,000 | |
| Option Care Health, Inc. |
1.56%
65,000
|
$1,800,500,000 | 0.73% |
| Humana Inc. |
No change
4,751
|
$1,775,211,000 | 0.72% |
| Astrazeneca |
11.38%
21,650
|
$1,688,484,000 | 0.69% |
| Acelyrin Inc |
Closed
244,000
|
$1,647,000,000 | |
| Stevanato Group Spa |
Opened
89,000
|
$1,632,260,000 | 0.66% |
| Evolent Health Inc |
Opened
84,000
|
$1,606,080,000 | 0.65% |
| Insulet Corporation |
59.39%
7,350
|
$1,483,230,000 | 0.60% |
| Edwards Lifescience |
No change
15,650
|
$1,445,591,000 | 0.59% |
| iTeos Therapeutics, Inc. |
27.62%
96,966
|
$1,438,975,000 | 0.58% |
| Biogen Inc |
11.91%
6,137
|
$1,422,679,000 | 0.58% |
| Effector Therapeutic |
Closed
95,305
|
$1,371,439,000 | |
| Turnstone Biologics |
No change
517,648
|
$1,356,238,000 | 0.55% |
| Olema Pharmaceutical |
15.36%
118,480
|
$1,281,954,000 | 0.52% |
| Bristol-Myers Squibb Co. |
Opened
30,000
|
$1,245,900,000 | 0.51% |
| Arcus Biosciences Inc |
16.29%
78,385
|
$1,193,804,000 | 0.49% |
| Cigna Group (The) |
Opened
3,500
|
$1,156,995,000 | 0.47% |
| Moonlake Immunothera |
53.71%
21,428
|
$942,189,000 | 0.38% |
| Altimmune Inc |
Closed
92,240
|
$939,003,000 | |
| Becton Dickinson |
Opened
4,000
|
$934,840,000 | 0.38% |
| Arvinas Inc |
28.60%
34,830
|
$927,175,000 | 0.38% |
| Verastem Inc |
Closed
74,200
|
$875,560,000 | |
| Cogent Biosciences I |
67.54%
85,600
|
$721,608,000 | 0.29% |
| ADC Therapeutics SA |
Opened
228,102
|
$720,802,000 | 0.29% |
| Insmed Inc |
40.19%
9,821
|
$658,007,000 | 0.27% |
| Illumina Inc |
7.48%
5,810
|
$606,448,000 | 0.25% |
| United Therapeutics Corp |
29.87%
1,820
|
$579,761,000 | 0.24% |
| Neurocrine Bioscienc |
6.20%
3,935
|
$541,731,000 | 0.22% |
| Incyte Corp. |
5.32%
8,905
|
$539,821,000 | 0.22% |
| Structure Therapeu |
124.09%
13,365
|
$524,844,000 | 0.21% |
| Roivant Sciences Ltd |
7.08%
45,957
|
$485,765,000 | 0.20% |
| Ionis Pharmaceutical |
4.36%
9,660
|
$460,396,000 | 0.19% |
| Medpace Holdings Inc |
14.33%
1,106
|
$455,506,000 | 0.19% |
| Intra Cellular Thera |
7.77%
6,530
|
$447,240,000 | 0.18% |
| Royalty Pharma plc |
14.26%
16,650
|
$439,061,000 | 0.18% |
| Blueprint Medicines Corp |
12.70%
3,850
|
$414,953,000 | 0.17% |
| Alkermes plc |
17.57%
16,730
|
$403,193,000 | 0.16% |
| Apellis Pharmaceutic |
8.17%
10,460
|
$401,246,000 | 0.16% |
| BridgeBio Pharma Inc |
3.54%
15,535
|
$393,502,000 | 0.16% |
| Ascendis Pharma A S |
33.53%
2,666
|
$363,589,000 | 0.15% |
| Jazz Pharma Plc |
14.38%
3,334
|
$355,838,000 | 0.14% |
| Sanofi |
42.15%
7,330
|
$355,652,000 | 0.14% |
| Beigene Limited |
33.72%
2,447
|
$349,113,000 | 0.14% |
| Dr Reddys Labs Ltd |
18.18%
4,500
|
$342,855,000 | 0.14% |
| Madrigal Pharmaceuti |
5.84%
1,065
|
$298,370,000 | 0.12% |
| Vera Therapeutics |
82.81%
7,718
|
$279,237,000 | 0.11% |
| Rocket Pharmaceutica |
15.40%
12,530
|
$269,771,000 | 0.11% |
| Crinetics Pharmace |
Opened
5,800
|
$259,782,000 | 0.11% |
| Exelixis Inc |
12.79%
11,460
|
$257,506,000 | 0.10% |
| Revolution Medicin |
48.88%
6,600
|
$256,146,000 | 0.10% |
| Denali Therapeutics Inc |
Closed
12,081
|
$247,902,000 | |
| Intellia Therapeut |
Closed
8,800
|
$242,088,000 | |
| Viatris Inc. |
Opened
22,500
|
$239,175,000 | 0.10% |
| Halozyme Therapeutic |
32.83%
3,815
|
$199,753,000 | 0.08% |
| Arrowhead Pharmaceut |
2.08%
7,522
|
$195,497,000 | 0.08% |
| Summit Therapeutics Inc |
92.06%
25,000
|
$195,000,000 | 0.08% |
| Biohaven Ltd |
Opened
3,900
|
$135,369,000 | 0.06% |
| Ptc Therapeutics I |
Opened
4,300
|
$131,494,000 | 0.05% |
| Scholar Rock Hldg |
2.40%
15,030
|
$125,200,000 | 0.05% |
| Perspective Therapeu |
Opened
11,000
|
$109,670,000 | 0.04% |
| Legend Biotech Corp |
33.33%
2,000
|
$88,580,000 | 0.04% |
| Kyverna Therapeutics |
No change
7,000
|
$52,500,000 | 0.02% |
| Zai Lab Ltd |
No change
2,000
|
$34,660,000 | 0.01% |
| Grail Inc |
Opened
240
|
$3,689,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 106 holdings | |||